Welcome to our dedicated page for DiagnaMed Holdings news (Ticker: DGNMF), a resource for investors and traders seeking the latest updates and insights on DiagnaMed Holdings stock.
About DiagnaMed Holdings Corp (DGNMF)
DiagnaMed Holdings Corp (CSE: DMED, OTCQB: DGNMF) is a pioneering healthcare technology and cleantech company focused on leveraging artificial intelligence (AI) and innovative solutions to address critical challenges in brain health and sustainable energy. Operating at the intersection of life sciences and clean energy, DiagnaMed is committed to advancing diagnostic tools, therapies, and hydrogen production technologies that redefine industry standards and improve global well-being.
BRAIN AGE® Brain Health AI Platform
At the core of DiagnaMed’s healthcare technology portfolio is the BRAIN AGE® Brain Health AI Platform, a groundbreaking AI-driven solution designed to estimate brain age and provide a comprehensive brain health score. This platform uses a low-cost electroencephalogram (EEG) headset to collect neural activity data, which is then analyzed using proprietary machine-learning algorithms. BRAIN AGE® offers a clinically validated assessment of brain resilience, vulnerability, and performance, enabling early detection of cognitive decline and personalized interventions. Its applications span healthcare clinics, sports therapy, mental health, and pharmaceutical research, addressing the needs of individuals, athletes, and patients with neurodegenerative conditions.
Innovations in Molecular Hydrogen Therapies
DiagnaMed is also exploring the therapeutic potential of molecular hydrogen for brain health. Molecular hydrogen has demonstrated antioxidant, anti-inflammatory, and neuroprotective effects in clinical studies, making it a promising adjunctive treatment for neurological disorders such as Alzheimer’s and Parkinson’s disease. The company is developing pharmaceutical-grade hydrogen therapies tailored for specific neurological and mental health conditions, further aligning with its mission to advance brain health solutions.
Hydrogen Production Technologies
In the cleantech sector, DiagnaMed is driving innovation in hydrogen production. The company collaborates with leading research institutions to develop cost-effective and sustainable methods for hydrogen extraction, including repurposing existing oil and gas infrastructure and leveraging proprietary electromagnetic heating technologies. These advancements aim to produce low-cost, carbon-neutral hydrogen, addressing the growing global demand for clean energy and supporting the transition to a low-carbon economy.
Strategic Partnerships and Industry Impact
DiagnaMed’s success is bolstered by strategic collaborations with academic institutions, clinical research organizations, and industry leaders. Partnerships with entities like Drexel University and the University of Miami validate the clinical utility of its BRAIN AGE® platform, while collaborations in the hydrogen sector position the company as a key player in sustainable energy innovation. By integrating cutting-edge AI diagnostics with scalable hydrogen solutions, DiagnaMed addresses critical needs in healthcare and energy, demonstrating its commitment to creating a healthier and more sustainable future.
Market Position and Differentiation
With a unique dual focus on brain health diagnostics and hydrogen production, DiagnaMed operates in two rapidly growing markets. The global digital brain health market, valued at approximately $199.98 billion in 2022, and the hydrogen energy market, projected to reach $556.56 billion by 2034, provide significant growth opportunities. DiagnaMed’s proprietary technologies, clinical validation, and cost-efficient solutions differentiate it from competitors, establishing its authority and trustworthiness in both industries.
Conclusion
DiagnaMed Holdings Corp is redefining innovation in healthcare and clean energy through its AI-driven brain health diagnostics and advanced hydrogen production technologies. By addressing critical challenges in brain health and sustainable energy, the company positions itself as a transformative force in two dynamic industries. Investors and stakeholders can look to DiagnaMed as a company committed to leveraging technology for meaningful impact, backed by expertise, strategic partnerships, and a focus on long-term value creation.
DiagnaMed Holdings (OTCQB: DGNMF) has received FDA Orphan Drug Designation for molecular hydrogen in treating Amyotrophic Lateral Sclerosis (ALS). This designation supports the development of treatments for this rare neuromuscular disease that affects approximately 50,000 people in the U.S. and Europe, with over 5,000 new cases annually.
Molecular hydrogen, known for its antioxidant and anti-inflammatory properties, has shown promising results in preclinical studies for mitigating oxidative stress and inflammation in ALS progression. The designation provides key benefits including tax credits for clinical trials, FDA fee exemptions, and potential seven-year market exclusivity upon approval.
Additionally, DiagnaMed has entered a non-binding letter of intent with Revive Therapeutics dated February 28, 2025, to acquire full rights to DiagnaMed's intellectual property related to molecular hydrogen for ALS. The acquisition is expected to close by March 31, 2025, subject to due diligence and definitive agreement.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has announced a private placement offering of units, targeting between $350,000 and $510,000 at $0.03 per unit. Each unit consists of one common share and one purchase warrant, with warrants exercisable at $0.05 for 24 months from closing.
The offering, led by EMD Financial Inc, will support:
- Research, development and commercialization of hydrogen production and monitor technology
- BRAIN AGE® Brain Health AI Platform
- General corporate and working capital purposes
The company may pay finder's fees including up to 8% cash commission and 8% finder warrants. The offering, closing around March 31, 2025, will be available to Canadian residents (except Quebec) under the Listed Issuer Financing Exemption, with no resale restrictions.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has announced its support for Québec Innovative Materials Corp (QIMC) in establishing hydrogen as a primary energy source in Quebec. This initiative aligns with Quebec's goals to reduce emissions by 38% by 2030 and achieve net-zero by 2050.
The collaboration focuses on QIMC's natural hydrogen production potential in the Lake Timiskaming Graben, specifically in St-Bruno-de-Guigues. DiagnaMed will support QIMC using its proprietary electromagnetic heating technology for hydrogen extraction, developed by Dr. Qingwang Yuan at Texas Tech University's HOPE Group.
According to CEO Fabio Chianelli, QIMC's St. Bruno-de-Guigues property findings could have a potential commercial value in the billions of dollars. The company aims to produce cost-effective, carbon-neutral hydrogen using their direct extraction technology.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) announces progress in commercializing its proprietary electromagnetic heating technology for hydrogen production. The technology, developed by Dr. Qingwang Yuan at Texas Tech University, enables direct hydrogen extraction from petroleum reservoirs and natural hydrogen fields.
The company is integrating this newly licensed technology into existing production systems to improve efficiency and cost-effectiveness. DiagnaMed has strengthened its partnership with Québec Innovative Materials Corp. (QIMC) to expand renewable energy applications.
DiagnaMed aims to repurpose over 25,000 active oil and gas fields and 2-3 million abandoned wells in the United States for hydrogen extraction. The company is currently in discussions with petroleum and natural hydrogen exploration companies for potential partnerships.
DiagnaMed Holdings Corp. (DGNMF) has announced a strategic collaboration with TerraVent Environmental Inc. to advance two hydrogen production technologies. The first technology, developed by Dr. Qingwang Yuan at Texas Tech University, combines hydraulic fracturing with electromagnetic heating to extract hydrogen from oil, gas, and shale reservoirs at costs as low as $0.86 per kilogram.
The second technology, developed by TerraVent, stimulates naturally occurring hydrogen generation using electromagnetic heat, with expected production costs at approximately half of the U.S. Department of Energy's $1/kg goal for 2031. The partnership will leverage existing infrastructure, including over 25,000 active oil and gas fields globally and 2-3 million abandoned wells in the United States.
This collaboration builds on DiagnaMed's recent partnership with Québec Innovative Materials Corp. at their St-Bruno-de-Guigues Hydrogen Project, where test results showed hydrogen concentration measurements reaching 7,119 ppm and maintaining 2,886 ppm, with several other measurements above 550 ppm.
DiagnaMed Holdings (CSE: DMED, OTCQB: DGNMF) has announced two significant corporate updates. First, Elyssia Patterson has resigned from the company's board of directors. Second, the company has issued 1,000,000 stock options to consultants with an exercise price of $0.05 per common share. These options have a five-year expiration term and will vest in four equal installments over a one-year period, with the first quarter vesting at three months and subsequent quarters vesting at six, nine, and twelve months from the grant date.
DiagnaMed Holdings Corp. (CSE: DMED, OTCQB: DGNMF) has announced a strategic partnership with Québec Innovative Materials Corp. (QIMC) to implement DiagnaMed's hydrogen extraction technology at QIMC's Ville Marie Hydrogen Project in Québec.
The collaboration centers on DiagnaMed's patented technology (WO2023044149A1), developed by Dr. Qingwang Yuan at Texas Tech University. This innovative method combines hydraulic fracturing with electromagnetic wave heating to extract hydrogen from various sources, including light oil, gas, shale reservoirs, and ultramafic rock formations.
The technology promises hydrogen production costs as low as $0.86 per kilogram, aligning with the U.S. Department of Energy's goal of achieving $1/kg hydrogen production by 2031. As part of the agreement, QIMC will receive 2,000,000 shares of DMED.
DiagnaMed Holdings (CSE: DMED, OTCQB: DGNMF), a frontrunner in hydrogen-producing technologies and AI medical applications, has announced a strategic partnership with Texas Tech University. This collaboration aims to commercialize a revolutionary technology (WO2023044149A1) for producing hydrogen directly from petroleum reservoirs and natural hydrogen fields.
Developed by Dr. Qingwang Yuan of the HOPE Group at Texas Tech, the technology combines hydraulic fracturing with electromagnetic wave heating to generate hydrogen from light oil, gas, and shale reservoirs, as well as ultramafic rock formations. With production costs potentially as low as $0.86 per kilogram, it aligns with the U.S. Department of Energy's goal of achieving $1/kg hydrogen by 2031.
Fabio Chianelli, Chairman and CEO of DiagnaMed, highlighted the technology's potential to transform over 25,000 active oil and gas fields globally and repurpose 2-3 million abandoned wells in the U.S. This innovation not only addresses global clean energy demands but also aims to reduce greenhouse gas emissions and deliver cost-effective, carbon-zero hydrogen.
Supported by a Techno-Economic Analysis from Argonne National Laboratory, this first-of-its-kind technology enhances energy efficiency and reduces costs and carbon footprints. As global hydrogen demand is expected to grow significantly, DiagnaMed’s partnership with Texas Tech positions it as a leader in the clean energy sector.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) has partnered with EIREX to develop and commercialize a novel hydrogen extraction technology from water. The EIREX technology aims to produce hydrogen at $0.25 per kilogram for pilot prototypes and $0.10 per kilogram for commercial units, significantly lower than the industry's 2030 target of $2 per kilogram. The global hydrogen market, valued at $170.14 billion in 2023, is expected to grow at a 9.3% CAGR through 2030. The collaboration focuses on developing commercial pilot prototypes and establishing partnerships with healthcare facilities for operational and medical treatment purposes.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has announced two key corporate actions: First, the company has granted 4.5 million stock options to directors, officers, and consultants at $0.05 per share, with a five-year expiration and quarterly vesting schedule over one year. Second, the board has approved a shares-for-debt settlement of $67,800 through the issuance of 1,356,000 common shares at $0.05 per share to an arm's length creditor.
FAQ
What is the current stock price of DiagnaMed Holdings (DGNMF)?
What is the market cap of DiagnaMed Holdings (DGNMF)?
What is DiagnaMed Holdings Corp's primary focus?
What is the BRAIN AGE® Brain Health AI Platform?
What industries does DiagnaMed operate in?
How does DiagnaMed contribute to hydrogen production innovation?
What are the applications of molecular hydrogen therapies?
Who are the target users of the BRAIN AGE® platform?
What differentiates DiagnaMed from its competitors?
What partnerships support DiagnaMed's innovations?
